These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

138 related articles for article (PubMed ID: 25314324)

  • 1. Funding sources for Canadian biorepositories: the role of user fees and strategies to help fill the gap.
    Barnes RO; Schacter B; Kodeeswaran S; ; Watson PH
    Biopreserv Biobank; 2014 Oct; 12(5):300-5. PubMed ID: 25314324
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A practical tool for modeling biospecimen user fees.
    Matzke L; Dee S; Bartlett J; Damaraju S; Graham K; Johnston R; Mes-Masson AM; Murphy L; Shepherd L; Schacter B; Watson PH
    Biopreserv Biobank; 2014 Aug; 12(4):234-9. PubMed ID: 25162459
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Biospecimen User Fees: Global Feedback on a Calculator Tool.
    Matzke LA; Babinszky S; Slotty A; Meredith A; Castillo-Pelayo T; Henderson MK; Simeon-Dubach D; Schacter B; Watson PH
    Biopreserv Biobank; 2017 Feb; 15(1):57-64. PubMed ID: 27576065
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Critical Financial Challenges for Biobanking: Report of a National Cancer Institute Study.
    Rao A; Vaught J; Tulskie B; Olson D; Odeh H; McLean J; Moore HM
    Biopreserv Biobank; 2019 Apr; 17(2):129-138. PubMed ID: 30638412
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The Biobank Economic Modeling Tool (BEMT): Online Financial Planning to Facilitate Biobank Sustainability.
    Odeh H; Miranda L; Rao A; Vaught J; Greenman H; McLean J; Reed D; Memon S; Fombonne B; Guan P; Moore HM
    Biopreserv Biobank; 2015 Dec; 13(6):421-9. PubMed ID: 26697911
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Generating a comprehensive set of standard operating procedures for a biorepository network-The CTRNet experience.
    Barnes R; Albert M; Damaraju S; de Sousa-Hitzler J; Kodeeswaran S; Mes-Masson AM; Watson P; Schacter B
    Biopreserv Biobank; 2013 Dec; 11(6):387-96. PubMed ID: 24835369
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Biobank bootstrapping: is biobank sustainability possible through cost recovery?
    Albert M; Bartlett J; Johnston RN; Schacter B; Watson P
    Biopreserv Biobank; 2014 Dec; 12(6):374-80. PubMed ID: 25496148
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Sustainability in a Hospital-Based Biobank and University-Based DNA Biorepository: Strategic Roadmaps.
    Seiler CY; Eschbacher J; Bowser R; LaBaer J
    Biopreserv Biobank; 2015 Dec; 13(6):401-9. PubMed ID: 26697909
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Certification for biobanks: the program developed by the Canadian Tumour Repository Network (CTRNet).
    Matzke EA; O'Donoghue S; Barnes RO; Daudt H; Cheah S; Suggitt A; Bartlett J; Damaraju S; Johnston R; Murphy L; Shepherd L; Mes-Masson AM; Schacter B; Watson PH
    Biopreserv Biobank; 2012 Oct; 10(5):426-32. PubMed ID: 24845043
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Financial stability in biobanking: unique challenges for disease-focused foundations and patient advocacy organizations.
    Bromley RL
    Biopreserv Biobank; 2014 Oct; 12(5):294-9. PubMed ID: 25313427
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Addressing the Challenge of Financial Sustainability in Biobanking.
    Campos AH; Schreeder M; Parry-Jones A; Abdelhafiz AS; Larson D; Pruetz B; Geddes T; Salman A; Lazaris A
    Biopreserv Biobank; 2015 Dec; 13(6):387-95. PubMed ID: 26697907
    [No Abstract]   [Full Text] [Related]  

  • 12. Relationship between pharmaceutical company user fees and drug approvals in Canada and Australia: a hypothesis-generating study.
    Lexchin J
    Ann Pharmacother; 2006 Dec; 40(12):2216-22. PubMed ID: 17132811
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Hidden costs: the direct and indirect impact of user fees on access to malaria treatment and primary care in Mali.
    Johnson A; Goss A; Beckerman J; Castro A
    Soc Sci Med; 2012 Nov; 75(10):1786-92. PubMed ID: 22883255
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Fee-for-service as a business model of growing importance: the academic biobank experience.
    McDonald SA; Sommerkamp K; Egan-Palmer M; Kharasch K; Holtschlag V
    Biopreserv Biobank; 2012 Oct; 10(5):421-5. PubMed ID: 23386922
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Securing the sustainability of biobanks].
    Kirsten R; Hummel M
    Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz; 2016 Mar; 59(3):390-5. PubMed ID: 26769112
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The Canadian Tissue Repository Network Biobank Certification and the College of American Pathologists Biorepository Accreditation Programs: Two Strategies for Knowledge Dissemination in Biobanking.
    Barnes RO; Shea KE; Watson PH
    Biopreserv Biobank; 2017 Feb; 15(1):9-16. PubMed ID: 27740852
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Biobank Finances: A Socio-Economic Analysis and Review.
    Gee S; Oliver R; Corfield J; Georghiou L; Yuille M
    Biopreserv Biobank; 2015 Dec; 13(6):435-51. PubMed ID: 26697914
    [TBL] [Abstract][Full Text] [Related]  

  • 18. National Health and Nutrition Examination Survey Biospecimen Program: NHANES III (1988-1994) and NHANES 1999-2014.
    McQuillan GM; McLean JE; Chiappa M; Corporation H; Lukacs SL
    Vital Health Stat 2; 2015 Jul; (170):1-14. PubMed ID: 26222898
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Removing user fees: learning from international experience to support the process.
    McPake B; Brikci N; Cometto G; Schmidt A; Araujo E
    Health Policy Plan; 2011 Nov; 26 Suppl 2():ii104-117. PubMed ID: 22027915
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nottingham Health Science Biobank: a sustainable bioresource.
    Matharoo-Ball B; Thomson BJ
    Biopreserv Biobank; 2014 Oct; 12(5):312-6. PubMed ID: 25340939
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.